Literature DB >> 7751321

Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase.

A Magull-Seltenreich1, W J Zeller.   

Abstract

In nine human colon tumour cell lines the relationship between O6-alkylguanine-DNA alkyltransferase (O6-AGT) activity and carmustine resistance was investigated. Three lines with O6-AGT activity below 25 fmol/mg protein had carmustine ED50 values ranging from 5.0 microM to 11.9 microM; six lines displaying an O6-AGT activity above 240 fmol/mg protein had ED50 values ranging from 28.9 microM to 69.5 microM. In lines with low O6-AGT activity, depletion of the repair protein by O6-benzylguanine resulted in a marginal increase of carmustine cytotoxicity (sensitization factors less than 2). In the majority of cell lines with high O6-AGT activity, pretreatment with O6-benzylguanine resulted in a pronounced sensitization to carmustine. In one line, an optimal time schedule for sensitization of colon tumour cells by O6-benzylguanine was assessed; continuous exposure to O6-benzylguanine > or = 16 h after carmustine exposure) was superior to short-term exposure limited to a period before carmustine treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751321     DOI: 10.1007/BF01366966

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  20 in total

Review 1.  Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.

Authors:  A E Pegg
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

2.  Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.

Authors:  M E Dolan; R B Mitchell; C Mummert; R C Moschel; A E Pegg
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

3.  Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine.

Authors:  S L Gerson; N A Berger; C Arce; S J Petzold; J K Willson
Journal:  Biochem Pharmacol       Date:  1992-03-03       Impact factor: 5.858

4.  Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.

Authors:  S M Redmond; F Joncourt; K Buser; A Ziemiecki; H J Altermatt; M Fey; G Margison; T Cerny
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

Review 5.  Repair of DNA containing O6-alkylguanine.

Authors:  A E Pegg; T L Byers
Journal:  FASEB J       Date:  1992-03       Impact factor: 5.191

6.  Pronounced damage of intestinal tract mucosa by the combination of 1-methyl-1-nitrosourea plus 1,3-bis-(2-chloroethyl)-1-nitrosourea. Effect of drug sequence and time interval of administration.

Authors:  W J Zeller; D Komitowski
Journal:  Toxicol Lett       Date:  1986 Jul-Aug       Impact factor: 4.372

7.  More than additive toxicity of the combination of 1-methyl-1-nitrosourea plus 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat.

Authors:  W J Zeller; M R Berger; T Henne; E Weber
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

8.  Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.

Authors:  B Gerard; S Aamdal; S M Lee; S Leyvraz; C Lucas; M D'Incalci; J P Bizzari
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

9.  Effects of streptozotocin/bis-chloroethylnitrosourea combination therapy on O6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro.

Authors:  R O Pieper; B W Futscher; Q Dong; L C Erickson
Journal:  Cancer Res       Date:  1991-03-15       Impact factor: 12.701

10.  Depletion of O6-methylguanine-DNA methyltransferase and potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea antitumor activity by O6-benzylguanine in vitro.

Authors:  J M Chen; Y P Zhang; R C Moschel; M Ikenaga
Journal:  Carcinogenesis       Date:  1993-05       Impact factor: 4.944

View more
  4 in total

1.  4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.

Authors:  Rui Zhu; Mao-Chin Liu; Mei-Zhen Luo; Philip G Penketh; Raymond P Baumann; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  J Med Chem       Date:  2011-10-17       Impact factor: 7.446

2.  Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

Authors:  Narin Apisarnthanarax; Gary S Wood; Seth R Stevens; Sean Carlson; Derek V Chan; Lili Liu; Sarolta K Szabo; Pingfu Fu; Anita C Gilliam; Stanton L Gerson; Scot C Remick; Kevin D Cooper
Journal:  Arch Dermatol       Date:  2012-05

Review 3.  Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.

Authors:  Michael D Milsom; David A Williams
Journal:  DNA Repair (Amst)       Date:  2007-05-07

4.  3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.

Authors:  S R Wedge; J K Porteous; E S Newlands
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.